In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
T cells and enhances immunotherapy-induced tumor regression in mice. These investigations yield insight into aPD-1 target engagement in vivo and identify specific Fc/FcγR interactions that can be modulated to improve checkpoint blockade therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Real-time in vivo imaging allows one to identify not only primary targets of immunotherapeutics (drug pharmacokinetics) (Arlauckas et al., 2017) but also how the tumor microenvironment responds to treatment (drug pharmacody namics).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Arlauckas et al., 2017
In the citing paper
“Most recently, a study revealed another unexpected resistance mechanism to anti-PD-1 therapy in mice whereby tumor-associated macrophages removed the therapeutic antibody from the surface of the T cells in vivo, thus making them once again susceptible to inhibitory signaling through the receptor.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
In the citing paper
“This phenomenon could be partially overcome by administration of Fc-receptor blocking agents prior to treatment (114).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cited by
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Immunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“An interesting example is to block Fc receptors on TAM which avoid depletion of anti-PD1 antibodies and therefore enhances the efficiency of the checkpoint therapy [92, 108].”
BackgroundMechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
“Recently, tumour-associated macrophages were demonstrated to directly limit PD-1 blockade by removing anti-PD-1 antibodies from PD-1þ CD8þ T cells in a FcgR-dependent manner (Arlauckas et al, 2017).”
BackgroundAnti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
“Macrophages may also interfere with anti-tumor immunity or even directly restrict therapeutic antibodies (114).”
BackgroundRodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Self-citationTargeting tumor-associated macrophages to synergize tumor immunotherapy
Xiang, X., Wang, J., Lu, D., & Xu, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00484-9 · Cited by 966
“In mouse models and primary human immune cells, anti-PD-1 antibodies were observed to be seized by macrophages depending on the Fc domain of the antibody and the FcγR expressed by macrophages, which led to ICI therapy resistance.(106) Moreover, a recent study has shown that Fc-FcγR binding-mediated TAM reprogramming c…”
BackgroundNear‐Infrared‐II Molecular Dyes for Cancer Imaging and Surgery
Zhu, S., Tian, R., Antaris, A. L., Chen, X., & Dai, H. (2019) · Advanced Materials · doi:10.1002/adma.201900321 · Cited by 972
Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966
Self-citationCancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Barrin, S., Kantari-Mimoun, C., Bercovici, N., Guérin, M., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720948115 · Cited by 919
“Unrelated to the latter mechanisms, it has recently been suggested that TAMs promoted resistance to anti–PD-1 strategy through another mechanism dependent on Fc receptors and the removal of the monoclonal antibody from T cells (48).”
BackgroundGlioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
Self-citationTargeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 625
Wang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H., Hu, X., Liu, Z., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3682 · Cited by 591
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 471
Combining Nanomedicine and Immunotherapy
Shi, Y., & Lammers, T. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00148 · Cited by 457
T cell‐targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
Schmid, D., Park, C. G., Hartl, C. A., Subedi, N., Cartwright, A. N., Puerto, R. B., Zheng, Y., Maiarana, J., Freeman, G. J., Wucherpfennig, K. W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01830-8 · Cited by 449
“This fi nding may be rather important, as it has recently been shown that anti-PD-1 antibodies (full IgG with intact Fc) are quickly removed from T cells by tumor-associated macrophages, which thereby reduce the ef fi cacy of the immunotherapy 18 .”
BackgroundSelf-citationTumor-associated macrophages in breast cancer: Innocent bystander or important player?
Qiu, S.-Q., Waaijer, S. J. H., Zwager, M. C., de Vries, E. G. E., van der Vegt, B., & Schröder, C. P. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.010 · Cited by 425
“Intravital imaging of a MC38 colon cancer allograft illustrated that macrophages mediated PD-1 therapy resistance through capturing the PD-1 antibody by the Fcγ receptor, thereby preventing T cell drug exposure [76].”
BackgroundLo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1390 · Cited by 408
“Cells of myeloid origin present in the tumormicroenvironment decrease the effects of ICI via PD-L1 expression (19), by "stealing" anti–PD-1 antibody from the membrane of T lymphocytes that return to anergy (20) or by secreting immunosuppressive molecules (21).”
BackgroundRoles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Zhang, H., Liu, L., Liu, J., Dang, P., Hu, S., Yuan, W., Sun, Z., Liu, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01725-x · Cited by 389
“Specifically, TAMs capture anti-PD-1/PD-L1 through Fcg receptors present on the cell surface [59].”
BackgroundFu, Y., Liu, S., Zeng, S., & Shen, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1396-4 · Cited by 390
“Notably, recent evidence indicates that PD-1 TAMs can capture anti-PD-1 monoclonal antibodies (aPD-1 mAbs) through Fcγ receptors (FcγRs) expressed on the surface binding to drug’s Fc domain glycan [45].”
BackgroundLessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 381
“Pittet and colleagues show that TAMs can capture PD-1 targeting antibodies on the T cell surface thereby considerably limiting the duration of drug efficacy [99], whereas in another paper, Weissman and collaborators reveal that TAMs also express PD-1 on their surface, which impairs their phagocytic activity [100].”
BackgroundThe Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Qin, W., Hu, L., Zhang, X., Jiang, S., Li, J., Zhang, Z., & Wang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02298 · Cited by 369
“Moreover, anti-PD-1 antibody binding to Fc receptors expressed on tumor-associated macrophages can partially be removed from tumors, which may reduce the effect of PD-1 antibodies (183).”
BackgroundMechanisms of Cancer Resistance to Immunotherapy
Bai, R., Chen, N., Li, L., Du, N., Bai, L., Lv, Z., Tian, H., & Cui, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01290 · Cited by 353
“A study showed that Fc domain glycan of the drug and Fcγ receptor (FcγR) expressed by the host bone marrow cells could determine the ability of PD-1 TAMs to capture anti–PD-1 drugs from the surface of T cells, which leads to PD-1 inhibitor resistance (99).”
BackgroundMajor pathways involved in macrophage polarization in cancer
Kerneur, C., Cano, C. E., & Olive, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026954 · Cited by 337
“The ability of TAMs to limit the efficacy of immune checkpoint blockade therapy has been reported in several studies (83).”
BackgroundArg1 expression defines immunosuppressive subsets of tumor-associated macrophages
Arlauckas, S. P., Garren, S. B., Garris, C. S., Kohler, R. H., Oh, J., Pittet, M. J., & Weissleder, R. (2018) · Theranostics · doi:10.7150/thno.26888 · Cited by 331
“Myeloid cells and TAM in particular have been indicated in immunotherapy resistance [10,34,45]; however, the changes incurred during successful immunotherapy have, as of yet, not been fully examined.”
BackgroundMethodSelf-citationCurrent Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Anfray, C., Ummarino, A., Andón, F. T., & Allavena, P. (2019) · Cells · doi:10.3390/cells9010046 · Cited by 304
“demonstrated that anti‐ PD‐1 co‐localizes with T cells for just a short period (0.5h), then the antibody was captured by TAMs for longer time (20 h), de facto hampering the efficacy of the ICB [43].”
BackgroundInfluentialTumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
Pu, Y., & Ji, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.874589 · Cited by 297
“Moreover, TAMs can prevent the interaction of anti-immune checkpoint mAbs with the targets through the Fcg receptor present on cell surfaces (53).”
BackgroundNakamura, Y., Kawazoe, A., Lordick, F., Janjigian, Y. Y., & Shitara, K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00492-2 · Cited by 298
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
Zhang, T., Song, X., Xu, L., Ma, J., Zhang, Y., Gong, W., Zhang, Y., Zhou, X., Wang, Z., Wang, Y., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2160-x · Cited by 290
“recently showed in a mouse model that anti-PD-1 antibody could be transferred from PD-1+ T cells to macrophages via FcγR-dependent manner [45], supporting our findings that tumor-associated macrophages and FcγRI can negatively impact on anti-PD-1 antibody-mediated anti-tumor efficacy.”
ResultPD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 288
“Moreover, a study showed that in vivo PD-1− tumor-associated macrophages removed anti-PD-1 mAbs from the surface of PD-1+CD8+ T cells, mediated by the interaction between FcγII/III receptors and the anti-PD-1 Fc domain glycan (353).”
BackgroundEmerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 275
“7b).(365,366) Therefore, Fc-engineered IgG variants that disrupt FCR binding and combination therapies with agents that inhibit FcγR binding are better options for immunotherapy.”
BackgroundHu, W., Zi, Z., Jin, Y., Li, G., Shao, K., Cai, Q., Ma, X., & Wei, F. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2281-2 · Cited by 265
Kundu, M., Butti, R., Panda, V. K., Malhotra, D., Das, S., Mitra, T., Kapse, P., Gosavi, S. W., & Kundu, G. C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01990-4 · Cited by 250
“Moreover, TAMs express Fc receptors that inhibit the binding of anti-PD1 antibodies to T cells, thereby preventing the suppression of PD1/PD-L1 signaling, leading to resistance to anti-PD1 therapy using in vivo tumor models [172].”
MethodTumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis
Jeong, H., Kim, S., Hong, B.-J., Lee, C.-J., Kim, Y.-E., Bok, S., Oh, J.-M., Gwak, S.-H., Yoo, M. Y., Lee, M. S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2545 · Cited by 268
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Nakamura, T., Sato, T., Endo, R., Sasaki, S., Takahashi, N., Sato, Y., Hyodo, M., Hayakawa, Y., & Harashima, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002852 · Cited by 257
Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy
Wang, C., Zeng, Q., Gül, Z. M., Wang, S., Pick, R., Cheng, P., Bill, R., Wu, Y., Naulaerts, S., Barnoud, C., et al. (2024) · Cell · doi:10.1016/j.cell.2024.04.015 · Cited by 246
Self-citationFc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
Liu, R., Oldham, R., Teal, E., Beers, S., & Cragg, M. (2020) · Antibodies · doi:10.3390/antib9040064 · Cited by 238
“For example with anti-PD1 antibodies, residual FcγR binding has been implicated in the removal of the anti-PD1 mAb from the target cell by myeloid effectors [147].”
BackgroundSantoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 237
Kwon, M., An, M., Klempner, S. J., Lee, H., Kim, K.-M., Sa, J. K., Cho, H. J., Hong, J. Y., Lee, T., Min, Y. W., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0219 · Cited by 237
He, W., Kapate, N., Shields, C. W., & Mitragotri, S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.12.001 · Cited by 236
Waterhouse, D. M., Garon, E. B., Chandler, J., McCleod, M., Hussein, M., Jotte, R., Horn, L., Daniel, D. B., Keogh, G., Creelan, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00131 · Cited by 235
“It is plausible that early relapse observed with discontinuation of immunotherapy, regardless of tumor type, may be caused by loss of PD-1/PD-L1 inhibition,(17) potentially because of rapid antibody clearance resulting in a short on-target treatment lifespan in the local tumor environment.(18) Resistance mechanisms ma…”
BackgroundPowley, I. R., Patel, M., Miles, G., Pringle, H., Howells, L., Thomas, A., Kettleborough, C., Bryans, J., Hammonds, T., MacFarlane, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0672-6 · Cited by 218
“There is now strong evidence for extensive inter- and intra-tumour heterogeneity both within and between human cancer samples(10,11) and for a critical role of the tumour microenvironment (TME) in driving cancer hallmarks and in influencing drug responses.(12,13) Indeed, the previous lack of appreciation for the diver…”
BackgroundInnate Immunity and Cancer Pathophysiology
Maiorino, L., Daßler-Plenker, J., Sun, L., & Egeblad, M. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032221-115501 · Cited by 215
Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide
Lee, C., Jeong, H., Bae, Y., Shin, K., Kang, S., Kim, H., Oh, J., & Bae, H. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0610-4 · Cited by 211
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 191
“The potential of PD-1 − TAMs to capture anti-PD-1 antibodies from the surface of PD-1 + tumor-infiltrating T cells was also shown to mediate the resistance to PD-1 blockade [175].”
Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer
Vennin, C., Murphy, K. J., Morton, J. P., Cox, T. R., Pajic, M., & Timpson, P. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.280 · Cited by 202
Pang, X., Huang, Z., Zhong, T., Zhang, P., Wang, Z. M., Xia, M., & Li, B. (2023) · mAbs · doi:10.1080/19420862.2023.2180794 · Cited by 193
“PD-1 expressing T cells and compromise the anti-tumor efficacy of anti-PD-1 antibody.(17) On the other hand, recent literature”
BackgroundCassetta, L., & Kitamura, T. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00038 · Cited by 200
“In contrast, addition of FcγR blocking antibodies to the anti-PD1 treatment completely suppresses tumor growth in all mice (Arlauckas et al., 2017).”
BackgroundInfluentialMetabolism in tumor microenvironment: Implications for cancer immunotherapy
Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 198
Park, Y.-J., Kuen, D.-S., & Chung, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0130-1 · Cited by 194
Tumor Abnormality-Oriented Nanomedicine Design
Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 188
Voloshin, T., Kaynan, N., Davidi, S., Porat, Y., Shteingauz, A., Schneiderman, R. S., Zeevi, E., Munster, M., Blat, R., Tempel Brami, C., et al. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02534-7 · Cited by 179
Tumor-Associated Macrophage Status in Cancer Treatment
Malfitano, A. M., Pisanti, S., Napolitano, F., Di Somma, S., Martinelli, R., & Portella, G. (2020) · Cancers · doi:10.3390/cancers12071987 · Cited by 184
“TAMs are known to limit the efficacy of ICB therapy [105,106] because they express ligands of checkpoint receptors like PD-L1, PD-L2, CD80, CD86, the V-domain immunoglobulin suppressor of T cell activation (VISTA).”
BackgroundLinking macrophage metabolism to function in the tumor microenvironment
Jin, R., Neufeld, L., & McGaha, T. L. (2025) · Nature Cancer · doi:10.1038/s43018-025-00909-2 · Cited by 166
“In addition to direct influences on cancer cells and stroma, TAMs can promote resistance against chemotherapy and immunotherapy 5,6 and inhibit cytotoxic immune cell function in the tumor 7 .”
Chen, X., Song, X., Li, K., & Zhang, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00292 · Cited by 174
“The blockade of FcγRs could thus prolong the binding of the anti-PD-1 antibody to CD8 TILs and enhance the anti-tumor activity in vivo (74).”
BackgroundPD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
McGowan, E., Lin, Q., Ma, G., Yin, H., Chen, S., & Lin, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109625 · Cited by 171
“Thirdly, antiPD-1 mAbs can be captured prior to reaching the T cell surface by PD-1 tumor-associated macrophages through their Fc domain, removing their ability to block PD-1 and resulting in suppression of T cell function [113].”
BackgroundUnderstanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
Dougan, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01547 · Cited by 170
Macrophage targeting: opening new possibilities for cancer immunotherapy
Cassetta, L., & Kitamura, T. (2018) · Immunology · doi:10.1111/imm.12976 · Cited by 166
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 183
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
Aslan, K., Turco, V., Blobner, J., Sonner, J. K., Liuzzi, A. R., Núñez, N. G., De Feo, D., Kickingereder, P., Fischer, M., Green, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14642-0 · Cited by 162
Yang, L., & Lin, P. C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.001 · Cited by 155
“In addition, TAMs capture the PD-1 mAbs on the T cell surface thus compromise the effectiveness of immune therapeutics [45].”
BackgroundNanomedicine and macroscale materials in immuno-oncology
Sun, Q., Barz, M., Geest, B. G. D., Diken, M., Hennink, W. E., Kiessling, F. M., Lammers, T., & Shi, Y. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00473k · Cited by 163
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 151
“Further TAMs have been described to inhibit PD-1:PD-L1 therapy by removal of anti-PD-1 mAbs from PD-1 CD8 T cells using their FcγR (136).”
MethodInfluentialAnti–CTLA-4 therapy requires an Fc domain for efficacy
Ingram, J. R., Blomberg, O. S., Rashidian, M., Ali, L., Garforth, S., Fedorov, E., Fedorov, A. A., Bonanno, J. B., Le Gall, C., Crowley, S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801524115 · Cited by 150
“In contrast, PD-1–blocking antibodies may be removed from their targets by FcγR binding, reducing efficacy (40).”
BackgroundSelf-citationEngineering nanoparticle strategies for effective cancer immunotherapy
Yoon, H. Y., Selvan, S. T., Yang, Y., Kim, M. J., Yi, D. K., Kwon, I. C., & Kim, K. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.036 · Cited by 148
The molecular feature of macrophages in tumor immune microenvironment of glioma patients
Zhang, H., Luo, Y., Wu, W., Zhang, L., Wang, Z., Dai, Z., Feng, S., Cao, H., Cheng, Q., & Liu, Z. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.019 · Cited by 165
“Moreover, CD11+MHC-II+ macrophages are found to be capable of removing anti-PD-1 antibodies from CD8+ T cells by Fc domainFcc receptor interaction, thus neutralizing the therapeutic effect of PD-1 antibodies [91].”
BackgroundKim, H.-Y., Li, R., Ng, T. S. C., Courties, G., Rodell, C. B., Prytyskach, M., Köhler, R. H., Pittet, M. J., Nahrendorf, M., Weissleder, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b04338 · Cited by 151
Self-citationZhao, C., Tang, X., Chen, X. S., & Jiang, Z. (2024) · ACS Nano · doi:10.1021/acsnano.4c04022 · Cited by 142
Redefining macrophage and neutrophil biology in the metastatic cascade
Güç, E., & Pollard, J. W. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.022 · Cited by 140
Vuong, L. H., Kouverianou, E., Rooney, C. M., McHugh, B. J., Howie, S., Gregory, C. D., Forbes, S. J., Henderson, N. C., Zetterberg, F. R., Nilsson, U. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2244 · Cited by 155
“TAMs can also be important direct targets of PD-1/PD-L1 inhibition and can also promote drug resistance by removing anti-PD-1 antibodies from T cells (5, 6).”
BackgroundWu, A., Maxwell, R., Xia, Y., Cardarelli, P. M., Oyasu, M., Belcaid, Z., Kim, E. S., Hung, A. L., Luksik, A. S., Garzón-Muvdi, T., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03172-5 · Cited by 144
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
Qiu, Y., Chen, T., Hu, R., Zhu, R., Li, C., Ruan, Y., Xie, X., & Li, Y. (2021) · Biomarker Research · doi:10.1186/s40364-021-00327-3 · Cited by 158
Targeting the activity of T cells by membrane surface redox regulation for cancer theranostics
Shi, C., Zhang, Q., Yao, Y., Zeng, F., Du, C., Nijiati, S., Wen, X., Zhang, X., Yang, H., Chen, H., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01261-7 · Cited by 142
Applying artificial intelligence for cancer immunotherapy
Xu, Z., Wang, X., Zeng, S., Ren, X., Yan, Y., & Gong, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.007 · Cited by 126
“Arlauckas et al. 97 found that tumor-associated macrophages quickly removed anti-PD-1 monoclonal antibodies from T cells, thereby impairing the cytotoxic T cell responses.”
BackgroundToward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Fan, Q., Chen, Z., Wang, C., & Liu, Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802540 · Cited by 129
Targeting myeloid cells in the tumor sustaining microenvironment
Schupp, J., Krebs, F. K., Zimmer, N., Trzeciak, E., Schuppan, D., & Tuettenberg, A. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.013 · Cited by 126
Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma
Chakraborty, B., Byemerwa, J. K., Shepherd, J., Haines, C., Baldi, R., Gong, W., Liu, W., Mukherjee, D., Artham, S., Lim, F., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151347 · Cited by 137
Razak, A. R., Cleary, J. M., Moreno, V., Boyer, M., Calvo Aller, E., Edenfield, W., Tie, J., Harvey, R. D., Rutten, A., Shah, M. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001006 · Cited by 123
Bashraheel, S. S., Dömling, A. S. S., & Goda, S. K. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110009 · Cited by 140
Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models
Sharma, S. K., Chow, A. T., Monette, S., Vivier, D., Pourat, J., Edwards, K. J., Dilling, T. R., Abdel-Atti, D., Zeglis, B. M., Poirier, J. T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1958 · Cited by 129
Lurje, I., Hammerich, L., & Tacke, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197378 · Cited by 126
“Furthermore, TAMs have been shown to capture anti-PD-1 antibodies from CD8+ lymphocytes via the Fc domain, abrogating the checkpoint inhibition signal [142].”
BackgroundRole of Tumor-Associated Myeloid Cells in Breast Cancer
Cha, Y. J., & Koo, J. S. (2020) · Cells · doi:10.3390/cells9081785 · Cited by 125
“M1 macrophages in breast cancer are associated with increased cancer cell apoptosis, decreased metastasis, and cancer invasion [32,33].”
BackgroundTumor-Targeted Nanomedicine for Immunotherapy
Cabral, H., Kinoh, H., & Kataoka, K. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00518 · Cited by 123
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Griffin, M., Scotto, D., Josephs, D. H., Mele, S., Crescioli, S., Bax, H. J., Pellizzari, G., Wynne, M. D., Nakamura, M., Hoffmann, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19836 · Cited by 130
“Studies also point to tumor-associated macrophages as potential decoy cells by sequestering anti-PD-1 antibodies away from their T cell targets through Fc gamma receptor engagement [68].”
BackgroundYagi, T., Baba, Y., Okadome, K., Kiyozumi, Y., Hiyoshi, Y., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.01.018 · Cited by 123
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 124
“Although anti–PD-1 antibodies could initially bind to T cells as intended, the TAMs quickly removed these antibodies from T cells, thus inactivating them (37).”
BackgroundKo, J., Wilkovitsch, M., Oh, J., Köhler, R. H., Bolli, E., Pittet, M. J., Vinegoni, C., Sykes, D. B., Mikula, H., Weissleder, R., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01339-6 · Cited by 121
Self-citationIntravital imaging to study cancer progression and metastasis
Entenberg, D. R., Oktay, M. H., & Condeelis, J. S. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00527-5 · Cited by 134
Dobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052847 · Cited by 131
“Even more importantly, TAMs are able to inhibit the anticancer response of the T cells, for example through the extensive expression of molecules as: PD-L1, TGF-β, ARGI and PGE2, but also producing chemokine CCL22, which causes accumulation of the Treg cells within the TME, enhancing the immunosuppressive conditions […”
BackgroundCancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
Shi, T., Ma, Y., Yu, L., Jiang, J., Shen, S., Hou, Y., & Wang, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051389 · Cited by 115
“Lastly, similar to MDSCs, TAMs and TANs can produce cytokines and chemokines (TGF-β, IL-10, CCL22, B7-H1/H4, and ROS) to interact with MDSCs, Th, TC, Treg, DCs and NK cells, finally enhancing the inhibitory effects of immunosuppressive checkpoints.”
BackgroundInfluentialZhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 145
“Measures to block Fc/FcgR binding inhibit the transfer of antiPD-1 mAbs from CD8 T cells to macrophages in vivo, thereby strengthening the therapeutic effect of anti-PD-1 (92).”
BackgroundLiu, J., Wang, Y., Tian, Z., Lin, Y., Li, H., Zhu, Z., Liu, Q., Su, S., Zeng, Y., Jia, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30569-0 · Cited by 111
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Javed, S. A., Najmi, A., Ahsan, W., & Zoghebi, K. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383456 · Cited by 121
“Within TME, the SMIs displayed higher diffusion rate in comparison to antibodies and able to target PD-1 protein in the other cellular sources, which could avoid the macrophage-mediated resistance that is the case with therapies involving anti-PD-1 antibodies (82).”
BackgroundWaight, J. D., Chand, D., Dietrich, S., Gombos, R., Horn, T., Gonzalez, A. M., Manrique, M., Swiech, L., Morin, B., Brittsan, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.005 · Cited by 104
Metadata
- Authors
- Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., Weissleder, R., & Pittet, M. J.
- Affiliations
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, MA 02114, USA.
- Massachusetts General Hospital (US)
- Corresponding author
- Arlauckas, Sean P.
- Garris, Christopher S.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-05-10
- Volume
- 9
- Issue
- 389
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5734617
- OpenAlex
- W2612649234
- Cited by
- 669
- References
- 55
- Citations by year
- 2026: 50 · 2025: 57 · 2024: 76 · 2023: 75 · 2022: 84 · 2021: 98 · 2020: 87 · 2019: 62 · 2018: 50 · 2017: 29
- FWCI
- 27.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Funders
- National Institutes of Health (award301192, 5P50CA086355, award301190, R01AI084880, award301193, R21CA190344, award301191, U54-CA151884)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-associated macrophages, anti-PD-1 therapy, immune checkpoint inhibitor resistance, T cell activation, tumor regression, in vivo imaging, target engagement
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Humans, Immunotherapy, Mice, Inbred C57BL, Receptors, IgG, CD8-Positive T-Lymphocytes, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.